[US Stock Movement] Savara Surges on November 19: FDA Approval Approaching, High Short Interest, and Clinical-Stage Biopharmaceutical Company
Bitget异动解读2026/11/19 19:01Savara November 19th Major Surge Interpretation
Keywords: FDA approval approaching, high short interest, clinical-stage biopharma company
1. Media reports on November 16th indicated that the U.S. Food and Drug Administration (FDA) is expected to make a decision on November 22nd regarding the Biologics License Application for MOLBREEVI for autoimmune pulmonary alveolar proteinosis. JPMorgan previously gave the stock an overweight rating and set a target price of $12.
2. Data from November 18th shows that approximately 32.27 million Savara shares have been sold short, accounting for about 24.87% of the float. Based on recent trading volume, the estimated days to cover is approximately 12.94 days.
3. The company is a clinical-stage biopharmaceutical enterprise, and its only pipeline project, MOLBREEVI, is an inhaled granulocyte-macrophage colony-stimulating factor for autoimmune pulmonary alveolar proteinosis. It has submitted marketing applications in the U.S., EU, and UK, which are currently under review.
(Disclaimer: This content is summarized and generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hedge Funds are Dumping AI Stocks at a Record Pace. Where Is the Money Going?
